We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Newly Discovered Protein Blocks Tumor Growth

By Biotechdaily staff writers
Posted on 18 Nov 2004
Investigators have discovered that a form of vascular endothelial growth factor (VEGF) present in normal blood and tissue can prevent tumor growth. More...


A team of scientists at Bristol University (UK) has called the new type of factor VEGF165b, which was found to inhibit the growth of new blood vessels required for tumors to grow greater than 1 mm. The scientists have also found that VEGF is usually found in many areas of the body, including the prostate, but not in prostate tumors, and have figured out how this form of VEGF works with blood vessels.

Knowing how VEGF165b functions, and its effects on tumors, means that it could be possible to prevent the growth of tumors by starving the tumor using the body's own antitumor agent. The benefits of using this protein over conventional compounds to treat cancer is that VEGF156b is a natural protein made by the body under normal conditions. Many new cancer treatments are based on depriving the tumor of nutrients by attacking the blood supply of the tumor rather than the cancer cells. Blocking VEGF using antibodies has recently been demonstrated to be effective in large-scale trials with colorectal cancer patients in the United States.

One problem with this therapy will be that new blood vessel growth is needed for many body processes. However, it is believed that adults can live normally without blood vessel growth for extended time periods.

"Now that we have found out that this protein works in living tissues, we need to find the best way of using it in cancer, with tumor models. We also need to try it in models of other diseases where blood vessel growth is necessary, such as diabetes, age-related macular degeneration, and arthritis,” said Dr. David Bates, from Bristol University.

Dr. Steve Harper, another researcher from Bristol University, stated, "After two years of hard work, it is a big step to show that this protein works in real cancers. We hope to be able to take this forward in the next few years to work out how to treat patients with cancer, eye disease, and other conditions where this protein is important.”




Related Links:
Bristol University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gastrointestinal Panel
Xpert® GI Panel
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Image: The LymphoTrack Flex suite is an integrated next-generation sequencing solution for identifying and tracking immunoglobulin and T-cell receptor gene rearrangements (Photo courtesy of Invivoscribe)

New NGS Suite Expands Clonality and MRD Research in Lymphoid Malignancies

Lymphoid malignancies require molecular tools that can distinguish clonal immune receptor rearrangements and track disease-related sequences over time. As immune receptor measurable residual disease analysis... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.